Skip to main content
Clinical Trials/NCT00365235
NCT00365235
Completed
Not Applicable

Genetic Susceptibility to Common Lipid Disorders in Mexico

University of California, Los Angeles1 site in 1 country998 target enrollmentJuly 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyperlipidemia, Familial Combined
Sponsor
University of California, Los Angeles
Enrollment
998
Locations
1
Primary Endpoint
Identifying the specific genes that predispose Mexican individuals to FCHL
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Familial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.

Detailed Description

CHD is the leading cause of death in Mexico. Dyslipidemia that is characterized by high total cholesterol, high triglycerides, and low "good" high-density lipoprotein (HDL) cholesterol is a risk factor for developing CHD. Research has shown that the Mexican population has an increased tendency towards dyslipidemia, but it is not known what genetic factors contribute to this predisposition. This study will examine the genetic basis of FCHL, which is an inherited form of dyslipidemia characterized by elevated levels of total cholesterol and triglycerides. FCHL is a major contributing factor in CHD; 20% of individuals with CHD under the age of 60 have FCHL. The purpose of this study is to identify and characterize the specific DNA sequence variations that predispose Mexican individuals to FCHL. Results of this study may aid in the development of appropriate prevention and screening techniques. This study will enroll individuals in Mexico who have FCHL. Participants will attend one study visit for blood collection and DNA sampling. Family members of participants will be contacted and asked to provide a DNA sample also. A select group of participants will return for a second study visit for RNA sampling. Study researchers will analyze participants' DNA and RNA samples, as well as two FCHL genes identified in previous research studies.

Registry
clinicaltrials.gov
Start Date
July 2006
End Date
June 2011
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Paivi Pajukanta

Professor

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • Elevated levels of serum total cholesterol, triglycerides, or both
  • Elevated levels of serum apolipoprotein B (using the Mexican population percentiles)

Exclusion Criteria

  • Tendon xanthomas
  • Kidney disease
  • Thyroid disorder

Outcomes

Primary Outcomes

Identifying the specific genes that predispose Mexican individuals to FCHL

Time Frame: Measured through the use of genetic samples

Study Sites (1)

Loading locations...

Similar Trials